Document Detail


2-Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography Demonstrates Target Inhibition with the Potential to Predict Anti-Tumour Activity Following Treatment with the AKT Inhibitor AZD5363.
MedLine Citation:
PMID:  23344784     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: The phosphatidyl inositol 3 kinase, AKT and mammalian target of rapamycin are frequently deregulated in human cancer and are among one of the most promising targets for cancer therapy. AZD5363 (AstraZeneca) is an AKT inhibitor in phase 1 clinical trials. Given its utility in assessing glucose metabolism, we investigated the role of 2-Deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) positron emission tomography (PET) as a biomarker to demonstrate target inhibition and its potential to predict and demonstrate the anti-tumour activity of AZD5363. METHODS: (18)F-FDG PETscans were performed in nude mice in a number of xenograft models (U87-MG glioblastoma, BT474C breast carcinoma and Calu-6 lung). Mice were fasted prior to imaging, and either static or dynamic (18)F-FDG PET imaging was performed. RESULTS: We have shown that (18)F-FDG uptake in tumour xenografts was reduced by 39 % reduction compared to vehicle after a single dose of AZD5363, demonstrating activation of the AKT pathway after only 4 h of dosing. Multiple doses of AZD5363 showed an anti-tumour volume effect and a reduction in (18)F-FDG uptake (28 % reduction compared to vehicle), highlighting the potential of (18)F-FDG PET as an efficacy biomarker. Furthermore, the degree of inhibition of (18)F-FDG uptake corresponded with the sensitivity of the tumour model to AZD5363. The use of dynamic (18)F-FDG PET and a two-compartmental analysis identified the mechanism of this change to be due to a change in cellular uptake of (18)F-FDG following administration of AZD5363. CONCLUSIONS: We conclude that (18)F-FDG PET is a promising pharmacodynamic biomarker of AKT pathway inhibition, with potential to predict and demonstrate anti-tumour activity. It is a biomarker that may stop ineffective drug schedules, helping to make early stop decisions and identify responding subsets of patients, resulting in improved clinical decision making both during drug development and patient management.
Authors:
Juliana Maynard; Sally-Ann Ricketts; Christelle Gendrin; Phillippa Dudley; Barry R Davies
Related Documents :
22760344 - Spectral ct of carotid atherosclerotic plaque: comparison with histology.
23638954 - Systematic review: mri enterography for assessment of small bowel involvement in paedia...
2349014 - Morphological diagnosis of congenital and acquired heart disease by magnetic resonance ...
25034274 - Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with...
17280864 - Removal of local and biased global maxima in intensity-based registration.
10768594 - Imaging of renal cell carcinoma.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-24
Journal Detail:
Title:  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging     Volume:  -     ISSN:  1860-2002     ISO Abbreviation:  Mol Imaging Biol     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101125610     Medline TA:  Mol Imaging Biol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Personalised Healthcare and Biomarkers, AstraZeneca, Cheshire, SK10 4TG, UK, Juliana.maynard@astrazeneca.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Parenting and risk for mood, anxiety and substance use disorders: a study in population-based male t...
Next Document:  Gallium(III) complexes with 2-acetylpyridine-derived thiosemicarbazones: antimicrobial and cytotoxic...